Latest News & Updates

Latest Articles
Patients with stage Ib-IVa resectable gastric adenocarcinoma undergoing surgery with curative intent had similar survival outcomes regardless of whether they received chemotherapy or chemoradiotherapy after surgery.
PUBLISHED: June 30, 2016
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome.
PUBLISHED: June 30, 2016
The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.
PUBLISHED: June 30, 2016
Adding MM-398 (irinotecan liposome injection; nal-IRI; Onivyde) to 5-fluorouracil and leucovorin had no negative effect on quality of life while significantly improving overall survival in patients with metastatic pancreatic cancer.
PUBLISHED: June 30, 2016
Reinhard Georg Dummer, MD, shares the encouraging phase III findings from the NEMO trial and how it shakes up the treatment paradigm for patients with NRAS-mutated melanoma.
PUBLISHED: June 30, 2016
Latest Peer Exchange Discussions
Panelists James M. Foran, MD, FRCPC, and Azra Raza, MD, provide insight on the current understanding in molecular testing and biomarkers in myelodysplastic syndrome. View Now
Panelists Mark A. Socinski, MD; Gregory J. Riely, MD, PhD; Jared Weiss, MD; Thomas E. Stinchcombe, MD; and Benjamin P. Levy, MD; provide insight on the treatment options in ALK-positive lung cancer. View Now
Online CME Activities
TitleExpiration DateCME Credits
Newer Options on the Horizon for Non-Small Cell Lung CancerJul 20, 20161.0
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 20, 20162.5
Advances in Next-Generation Sequencing in Precision Oncology: Solid TumorsJul 27, 20162.0
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Head and Neck CancersJul 31, 20162.5